ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced that it is relaunching the Allurion Balloon in France after ANSM, the ...

Research links weight loss medications like Ozempic and Zepbound to certain serious eye conditions.

Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.

Discover the truth in my Lipozem reviews – see how this weight loss supplement helped me lose pounds without extreme diets or ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Mad Muscles app review In recent years, fitness apps have become an integral part of the lives of millions of people seeking ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS candidate RFK Jr told senators the GLP-1s are ‘miracle drugs’ but shouldn’t ...